Terrance Coyne, MD

Dr. Coyne brings over 30 years of  hands-on experience in senior executive management (VP, SVP, Chief Medical Officer) of clinical development, medical affairs, R&D, business development and general management in the pharmaceutical, biotechnology and healthcare industries at large (3M, Abbott), medium (Celltech-Medeva), small (Encysive) and start-up (Metaphore, Genetix, Ventrus) companies.  

He has extensive experience preparing clinical development plans, clinical protocols, clinical study reports and executing translational and phase 1-4 clinical trials in a multitude of therapeutic categories (CV, CNS, Analgesics, Pulmonary/Respiratory, Allergy, GI, Anti-infective, Anti-inflammatory, Dermatologicals, Metabolic, Vaccines) and drug delivery technologies.  He has been intimately involved in the preparation of many IND, NDA/CTD, sNDA, ANDA and BLA submissions and in representing companies from the clinical/medical perspectives at governmental regulatory authorities in the US, Europe, Canada, Australia, etc.  Additionally, he has built and managed domestic and global medical affairs/medical services functions at a number of companies.  These functions included pharmacovigilance, medical information, advertising/promotional material review, medical aspects of sales training, publication and presentation planning and strategy, KOL development, Medical Science Liaisons, CME programs, Speaker’s Programs, Grant programs, Investigator Initiated Studies, presentations at major medical meetings, managed care, national accounts and governmental accounts, Risk Management Plan preparation, and development and management of Scientific and Clinical/Medical Advisory Boards.  He has also had broad involvement in due diligence and business development projects related to mergers, acquisitions, corporate partnering, product licensing, joint ventures, and divestitures throughout his career.   

Dr. Coyne received his B.S and M.D. degrees from the University of Wisconsin – Madison and after postgraduate training entered the private practice of medicine before entering the pharmaceutical industry.